Skip to main content
Evidence Snapshot

Middle East respiratory syndrome-related coronavirus

CHEMBL4296578 ORGANISM Middle East respiratory syndrome-related coronavirus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:25:28Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4296578
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Middle East respiratory syndrome-related coronavirus as ChEMBL target CHEMBL4296578. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Middle East respiratory syndrome-related coronavirus
ORGANISM · Middle East respiratory syndrome-related coronavirus
As of 2026-09-13
ChEMBL target ID
CHEMBL4296578
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Middle East respiratory syndrome-related coronavirus matters

As of 2026-09-13

Middle East respiratory syndrome-related coronavirus is reviewed as Middle East respiratory syndrome-related coronavirus; the current evidence base includes 18 approved drugs, 206 compounds, and 89 assays, with lead potency reaching pChEMBL 9.4.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 18 approved drugs, 206 compounds, and 89 assays for this target. The dominant activity type is EC50. CHEMBL4441971 is the current potency anchor at pChEMBL 9.4.

Use CHEMBL4441971 as the tractability anchor when discussing potency (pChEMBL 9.4).

Activity source · ChEMBL 36 via Core Engine
18 approved pChEMBL 9.4
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Middle East respiratory syndrome-related coronavirus matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

206
Total Compounds
89
Total Assays
18
Approved Drugs
IC50: 118.0, EC50: 127.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4441971
 9.4 EC50 —
No preferred name
CHEMBL555196
 8.9 EC50 —
No preferred name
CHEMBL4590737
 8.3 EC50 —
No preferred name
CHEMBL5179778
 8.3 EC50 —
No preferred name
CHEMBL3780681
 8.3 EC50 —

Approved Drugs

Structure Compound First Approval
NIRMATRELVIR
CHEMBL4802135
 2023
REMDESIVIR
CHEMBL4065616
 2020
GILTERITINIB
CHEMBL3301622
 2018
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:25:28Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4296578